Botulism News and Research

RSS

Botulism is a rare but serious paralytic illness caused by botulinum toxin, which is produced by the bacterium ''Clostridium botulinum''. The toxin enters the body in one of four ways: by colonization of the digestive tract by the bacterium in children (infant botulism) or adults (adult intestinal toxemia), by ingestion of toxin from foodstuffs (foodborne botulism) or by contamination of a wound by the bacterium (wound botulism).

IFR scientists mine the genome of C. botulinum to reveal new information about toxin genes

The toxin that causes botulism is the most potent that we know of. Eating an amount of toxin just 1000th the weight of a grain of salt can be fatal, which is why so much effort has been put into keeping Clostridium botulinum, which produces the toxin, out of our food.

15 May 2013

Juice products from Juices Incorporated have potential health risk, FDA warns

The U.S. Food and Drug Administration is warning consumers not to consume any juice products or other beverages from Juices Incorporated (aka Juices International and Juices Enterprises) of Brooklyn, N.Y.

13 May 2013

Botulism Antitoxin Heptavalent gets FDA approval for patients showing signs of botulism

The U.S. Food and Drug Administration announced today that it has approved Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin.

25 Mar 2013

Researchers call for botulism testing in sick and healthy cows

Evidence of Clostridium botulinum and its toxin in milk and udder tissue samples from dairy cows has led German researchers to call for “statistically relevant testing of healthy and sick cows from healthy and affected farms.”

14 Feb 2013

Neogen fourth quarter revenues increase 11.4% to $48,545,000

Neogen Corporation announced today that its revenues for the fourth quarter of its FY 2012, which ended May 31, increased 11.4% from the previous year's comparable quarter to $48,545,000. Net income for the fiscal year's final quarter was $0.25 per share, the same as the prior year's fourth quarter of $0.25 per share.

24 Jul 2012

Sandia researchers develop SpinDx medical diagnostic tool

Researchers at Sandia National Laboratories have developed a lab-on-a-disk platform that they believe will be faster, less expensive and more versatile than similar medical diagnostic tools.

14 Jul 2012

Novel strategy for neutralizing unwanted molecules and clearing them from the body

Researchers have unveiled a novel strategy for neutralizing unwanted molecules and clearing them from the body.

18 Jun 2012

Risk of botulism at California fish processing company

The U.S. Food and Drug Administration, in a complaint filed by the Department of Justice, is seeking to stop the processing and distribution of fish products at a California company because of a risk of botulism and other food hazards.

30 Mar 2012

Anthrax defenses need to be strengthened say experts

It has been a decade since the anthrax attacks brought home the reality of bioterrorism and the nation has a stockpile of some basic tools to fight back against a few of the threats that worry defense experts the most.

8 Jan 2012

Botulism toxins could be re-engineered for treating RA, asthma, psoriasis

The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases, scientists are reporting. Their study appears in ACS' journal Biochemistry.

1 Dec 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

Anthrax defenses need to be strengthened: Experts

It has been a decade since the anthrax attacks brought home the reality of bioterrorism and the nation now has a stockpile of some basic tools to fight back against a few of the threats that worry defense experts the most.

28 Sep 2011

Merz launches 'Make Your Mark' campaign to raise awareness on cervical dystonia

Merz Pharmaceuticals, LLC, maker of XEOMIN, a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.

15 Apr 2011

Cangene second quarter revenues increase 3% to $40.2 million

Cangene Corporation today reports financial results for the quarter ended January 31, 2011, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

18 Mar 2011

Illicit drug users may face increased risk of microbial infections

Illicit drug users are at increased risk of being exposed to microbial pathogens and are more susceptible to serious infections say physicians writing in the Journal of Medical Microbiology.

10 Mar 2011

Scientists sequence Clostridium botulinum genome that produces neurotoxin

Scientists on the Norwich Research Park have sequenced the genome of a novel strain of Clostridium botulinum, one of the most dangerous pathogens known to man. The strain produces an unusual botulinum neurotoxin, known as type A5 neurotoxin, which was isolated by the Health Protection Agency, following a case of wound botulism.

8 Mar 2011

New study identifies recurrent wound botulism among injection drug users

Botulism is a rare disease and recurrent botulism even more rare. However, in California, recurrent wound botulism among injection drug users has been on the rise and makes up three-quarters of reported cases in the United States.

28 Feb 2011

FDA stops operations of N.Y.-based beverage company

At the request of the U.S. Food and Drug Administration, the U.S. Department of Justice today filed a complaint for permanent injunction against a Jamaica, N.Y.-based beverage company to prevent it from processing and distributing juice and other products.

14 Jan 2011

Clostridium bacteria may offer a greener alternative to petrol

A diverse family of bacteria that can cause a potentially fatal illness in humans but could offer a greener alternative to petrol to power our cars will be the subject of a talk by a University of Nottingham academic at an international conference.

12 Jan 2011

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

30 Nov 2010